Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours.

ABSTRACT:

Background

Tumour immune microenvironment (TIME) of gastrointestinal stromal tumours (GISTs) is largely unknown.

Methods

A total of 81 surgical specimens from 67 patients with advanced GISTs were categorised into treatment groups: tyrosine kinase inhibitor (TKI)-naive, n = 20; imatinib-progressed and no exposure to sunitinib or regorafenib (IM-PD), n = 30; and imatinib-progressed and sunitinib and/or regorafenib-treated (IM-PD/SU-treated), n = 31. Multiplexed immunofluorescence staining and RNA sequencing were performed to define TIME.

Results

PD-L1 expression rate (>1%) of DOG-1⁺ tumour cells was 5.0, 6.7, and 29.0% in TKI-naive, IM-PD, and IM-PD/SU-treated group, respectively (p = 0.02). FoxP3 expression of CD3⁺ T cells and CD204⁺ CD

SUBMITTER: Yoo C 

PROVIDER: S-EPMC6888806 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature